1. Glannaventa, Inc.

    0 Comments Leave a Comment

    1-2 of 2
    1. Mentioned In 2 Articles

    2. Glannaventa Receives a NIH SBIR Grant for development of an out-patient screening procedure for high-grade serous ovarian cancer enabled by Optical Coherence Tomography.

      Glannaventa Receives a NIH SBIR Grant for development of an out-patient screening procedure for high-grade serous ovarian cancer enabled by Optical Coherence Tomography.
      Glannaventa Receives a 2021 NIH NCI SBIR Grant for $399,331 for development of an out-patient screening procedure for high-grade serous ovarian cancer enabled by Optical Coherence Tomography. The principal investigator is John Black. Below is a summary of the proposed work. This year, over 22,000 women in the U.S. will be diagnosed with ovarian cancer (OvCa), and ~14,000 will die from this disease. Approximately 9,000 ...
      Read Full Article
    3. Mechanical Engineer Endoscopy Job Opening at Glannaventa

      Mechanical Engineer Endoscopy Job Opening at Glannaventa
      Glannaventa is currently seeking an enthusiastic, creative medical device engineer to design, develop and implement critical components of the next-generation GEODE micro-endoscope and associated delivery system as part of our quest to develop an outpatient screening test for high-grade serous ovarian cancer. The majority of HGSOC, the most lethal histotype of ovarian cancer, is believed to originate in the epithelia of the distal Fallopian tubal structures, and then moves to ...
      Read Full Article
    4. 1-2 of 2
  1. Categories

    1. Applications:

      Art, Cardiology, Dentistry, Dermatology, Developmental Biology, Gastroenterology, Gynecology, Microscopy, NDE/NDT, Neurology, Oncology, Ophthalmology, Other Non-Medical, Otolaryngology, Pulmonology, Urology
    2. Business News:

      Acquisition, Clinical Trials, Funding, Other Business News, Partnership, Patents
    3. Technology:

      Broadband Sources, Probes, Tunable Sources
    4. Miscellaneous:

      Jobs & Studentships, Student Theses, Textbooks
  2. About Glannaventa, Inc.

    Glannaventa, Inc.

    Glannaventa, Inc. is a Puget Sound-based company developing an out-patient based endoscopic screening technique for early-stage fallopian-tube-origin epithelial ovarian cancer. The majority of high-grade serous ovarian cancer is believed to originate not on the ovary itself, but rather in the distal fallopian tube and fimbriae, with subsequent migration to the ovary and peritoneum. Beyond this point the disease is aggressive and metastatic but largely asymptomatic, and is typically only diagnosed at Stages 3/4 where the 5-year survival rate is around 25%. If the disease could be detected earlier, survival rates could be improved to over 90%. We are developing the GEODE(tm) micro-endoscope to image the carcinogenesis sites in the distal fallopian tube using both structural (OCT) and functional (multi-spectral fluorescence) imaging techniques. The falloposcope is capable of detecting early-stage lesions at a volume size 10 - 50 times smaller than the threshold for detecting a secreted biomarker or the reliable detection limits for TVUS, and should have a profound effect on our ability to detect this "silent killer".